Literature DB >> 9490672

Carboxyl-truncated STAT5beta is generated by a nucleus-associated serine protease in early hematopoietic progenitors.

J Meyer1, M Jucker, W Ostertag, C Stocking.   

Abstract

Hematopoiesis is tightly controlled by a family of cytokines that signal through a related set of receptors. The pleiotropic and overlapping response of a cell to different cytokines is reflected in the number and complex pattern of activated signal transducers. Of special interest is STAT5, which is stimulated by a large and diverse set of cytokines. In addition to the two highly homologous proteins, STAT5A and STAT5B, encoded by duplicated genes, expression and activation of a dominant-negative, carboxyl-truncated form has also been described in early hematopoietic progenitors. We show here that a protease expressed in early hematopoietic cells cleaves the alpha forms of STAT5A/5B (p96/p94) to generate carboxyl-truncated beta forms (p80/p77). Inhibition studies assigned this protease to the serine class of endopeptidases. Cell fractionation experiments showed that the protease is associated with the nucleus in a constitutively activated form and does not require an activated STAT5 substrate. The ability of a protease to modulate the specificity of an activated transcription factor is unprecedented and underlines the importance of proteases in regulation of cell functions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9490672

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  16 in total

1.  Murine serpin 2A is a redox-sensitive intracellular protein.

Authors:  Emma C Morris; Timothy R Dafforn; Sharon L Forsyth; Melinda A Missen; Anita J Horvath; Lynne Hampson; Ian N Hampson; Graeme Currie; Robin W Carrell; Paul B Coughlin
Journal:  Biochem J       Date:  2003-04-01       Impact factor: 3.857

Review 2.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

3.  An N-terminal splice variant of human Stat5a that interacts with different transcription factors is the dominant form expressed in invasive ductal carcinoma.

Authors:  Dunyong Tan; KuanHui E Chen; Changhui Deng; Peizhi Tang; Jianjun Huang; Trina Mansour; Richard A Luben; Ameae M Walker
Journal:  Cancer Lett       Date:  2013-12-30       Impact factor: 8.679

4.  Signal transduction activator of transcription 5 (STAT5) dysfunction in autoimmune monocytes and macrophages.

Authors:  S A Litherland; T X Xie; K M Grebe; A Davoodi-Semiromi; J Elf; N S Belkin; L L Moldawer; M J Clare-Salzler
Journal:  J Autoimmun       Date:  2005-03-23       Impact factor: 7.094

5.  Distinct gene-expression profiles characterize mammary tumors developed in transgenic mice expressing constitutively active and C-terminally truncated variants of STAT5.

Authors:  Tali Eilon; Itamar Barash
Journal:  BMC Genomics       Date:  2009-05-18       Impact factor: 3.969

6.  Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.

Authors:  Daniel C Wicke; Johann Meyer; Guntram Buesche; Dirk Heckl; Hans Kreipe; Zhixiong Li; Karl H Welte; Matthias Ballmaier; Christopher Baum; Ute Modlich
Journal:  Mol Ther       Date:  2009-10-20       Impact factor: 11.454

7.  Human tissue factor pathway inhibitor-2 is internalized by cells and translocated to the nucleus by the importin system.

Authors:  Prakasha Kempaiah; Hitendra S Chand; Walter Kisiel
Journal:  Arch Biochem Biophys       Date:  2008-12-10       Impact factor: 4.013

8.  STAT5 isoforms: controversies and clarifications.

Authors:  Haydeé L Ramos; John J O'Shea; Wendy T Watford
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

9.  Purification and identification of the STAT5 protease in myeloid cells.

Authors:  Björn Schuster; Lisa Hendry; Helen Byers; Steven F Lynham; Malcolm A Ward; Susan John
Journal:  Biochem J       Date:  2007-05-15       Impact factor: 3.857

10.  Modeling of molecular interaction between apoptin, BCR-Abl and CrkL--an alternative approach to conventional rational drug design.

Authors:  Soumya Panigrahi; Jörg Stetefeld; Jaganmohan R Jangamreddy; Soma Mandal; Sanat K Mandal; Marek Los
Journal:  PLoS One       Date:  2012-01-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.